Skip to main content
Clinical Trials/ChiCTR2600118381
ChiCTR2600118381Not yet recruitingNot Applicable

DUOX2 双等位基因突变的先天性甲减患者停药随访

自筹5 sites in 1 countryStarted: January 1, 2026Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Locations
5
Primary Endpoint
甲状腺功能

Study Overview

Brief Summary

明确 DUOX2 双等位基因突变的先天性甲减患者的临床转归

Study Design

Study Type
观察性研究
Primary Purpose
连续入组

Eligibility Criteria

Ages
3 to 12 (—)
Sex
All

Inclusion Criteria

  • 1.在新生儿筛查阶段确诊为先天性甲减;
  • 2.研究参与者的致病基因为 DUOX2;
  • 3.研究参与者大于等于 3 岁,小于 12 岁。

Exclusion Criteria

  • 1.甲状腺发育不全或甲状腺异位的先天性甲减患者;
  • 2.合并有其他甲状腺激素合成相关基因的双等位基因变异的患者;
  • 3.合并甲状腺激素受体基因变异患者。

Arms & Interventions

左甲状腺激素停药组

Outcomes

Primary Outcomes

甲状腺功能

甲状腺球蛋白

甲状腺大小

Secondary Outcomes

  • 体重
  • 身高
  • DUOX2 残留酶活性

Investigators

Sponsor
自筹

Study Sites (5)

Loading locations...

Similar Trials